AXSM Axsome Therapeutics, Inc.
AXSM Axsome Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $183.30 · VWAP $194.03 · -25.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
AXSM Price Structure
Loading timeframes…
Peers
Every watchlist AXSM belongs to, members best 30-day change first — AXSM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Axsome Therapeutics furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. Its 10-Q reports (GAAP): revenue $218M, diluted EPS -$0.99, net income -$51M.
full note →Against street estimates
How AXSM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about AXSM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 9 days ago · Oct 14
- Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
- Axsome Therapeutics to Report Second Quarter 2026 Financial
- Axsome Therapeutics Reports Fourth Quarter and ... - BioSpace
- Axsome Therapeutics, Inc. (AXSM) 8-K Earnings Release - Feb 2026
- Axsome Therapeutics Inc (AXSM) Live Share Price, Invest From India
AXSM research tape
53 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.